Clinical Trials Browser

NCT06010901 2024-01-23

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Phase 1 Unknown

75 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05028504 2023-12-27

ALTER-GO-020

Phase 2 Unknown

86 enrolled

Gynecological Cancer

NCT06062563 2023-10-02

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Phase NA Unknown

10 enrolled

EndocrineHead & Neck

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

NCT05783921 2023-07-28

A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Unknown

60 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05885399 2023-06-02

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Phase 2 Unknown

5 enrolled

CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05400876 2023-02-14

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Phase 1/2 Unknown

92 enrolled

Lymphoid

Lymphoma

NCT05726175 2023-02-13

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms

NCT05680038 2023-01-11

Penpulimab in Maintenance Therapy in Lymphoma

Unknown

167 enrolled

Lymphoid

Lymphoma

NCT05563480 2022-12-01

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Unknown

90 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05519202 2022-08-29

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

Phase 2 Unknown

47 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05485350 2022-08-03

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04970914 2022-03-08

ALTER-C003

Phase 2 Unknown

32 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Phase 2 Unknown

54 enrolled

Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT05265962 2022-03-04

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Phase 2 Unknown

85 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04952493 2022-01-28

Anlotinib or Penpulimab in Combination With RAI for DTC

Phase 2 Unknown

42 enrolled

Head & Neck

Thyroid Neoplasms